Alterity Therapeutics Raises A$20.0 million in Strategic Placement
1. Alterity raises A$20 million for clinical and regulatory activities. 2. Positive Phase 2 trial results for ATH434 bolster investor confidence. 3. Funding supports advancing drug development and potential strategic partnerships. 4. Shares priced at a 7.7% discount, aiming to strengthen financial position. 5. CEO reflects optimism about upcoming FDA engagement and approvals.